← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
U.S. Biotest, Inc
$8,587,388
Total funding
4
Grants
Funding over time
peak $4M · FY2015–21$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
DOD$8,587,388 · 4
By mechanism
—$8,587,388 · 4
Investigators at U.S. Biotest, Inc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
COVID-19 PHASE 2 CLINICAL EVALUATION OF USB002 (ANGIOTENSIN 1-7) FOR THE TREATMENT OF PULMONARY DISTRESS DUE TO COVID-19$4,031,922
· FY2021 · Defense Health Agency
CLINICAL SAFETY EVALUATION OF USB005 FOR TREATMENT OF TRAUMATIC CORNEAL LACERATIONS$2,749,052
· FY2016 · Department of Defense
NORLEU3-A(1-7) STIMULATES CORNEAL REPAIR AFTER INJURY$997,892
· FY2015 · Department of Defense
PHASE 2 ENABLING EVALUATIONS OF USB005 FOR TREATMENT OF CORNEAL INJURIES. NEW AWARD.$808,522
· FY2020 · Defense Health Agency